Takeda Pharmaceutical (TAK) holder plans sale of 15,188 ADSs under Form 144

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited reports a planned sale of 15,188 American Depositary Shares (ADSs) of its stock through Interactive Brokers LLC on the NYSE on July 13, 2026, with an aggregate market value of $254,398.88. The ADSs relate to previously issued equity compensation, and 143,310,556 shares of the issuer’s securities are reported as outstanding. During the prior three months, 38,982 ADSs tied to vested Restricted Stock Unit awards were sold on July 1, 2026 for compensation purposes.

Filing Explained

The filing proposes selling 38,982 Takeda ADSs from vested compensation awards, but does not show that a sale occurred or quantify proceeds.

The July 13, 2026 Form 144 reports a proposed sale of 38,982 ADSs of Takeda Pharmaceutical Company Limited; it identifies the securities as vested restricted stock unit awards acquired for compensation, so the filing records a planned disposition rather than a completed sale.

The filing does not provide a sale price, disclose a trading plan, or state the filer's remaining holdings, so it does not establish proceeds or the resulting change in that filer's ownership.

Key Figures

ADSs to be sold: 15,188 ADSs Aggregate market value of ADSs: $254,398.88 Shares outstanding: 143,310,556 shares +3 more

6 metrics

ADSs to be sold 15,188 ADSs Planned sale on NYSE through Interactive Brokers LLC on July 13, 2026

Aggregate market value of ADSs $254,398.88 Value associated with the 15,188 ADSs planned for sale

Shares outstanding 143,310,556 shares Issuer’s securities reported as outstanding in the Form 144

ADSs sold in past 3 months 38,982 ADSs Sale on July 1, 2026 from vested Restricted Stock Unit awards

Date of planned sale 07/13/2026 Scheduled NYSE transaction date for the 15,188 ADSs

Prior sale date 07/01/2026 Date of sale of 38,982 ADSs from vested RSU awards

Key Terms

Form 144, American Depositary Shares (ADSs), Restricted Stock Unit Awards, compensation

4 terms

Form 144 regulatory

"144: Securities To Be Sold ADSs | 07/01/2026 | Restricted Stock Unit"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

compensation financial

"38982 | 07/01/2026 | Compensation"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 06:30 AM Accepted by SEC EDGAR 07/13/2026 - 06:22 AM Learn about SEC filing dates

FAQ

What does Takeda Pharmaceutical (TAK) report in this Form 144 filing?

Takeda Pharmaceutical reports a planned sale of 15,188 ADSs on the NYSE, with an aggregate market value of $254,398.88, by a security holder, under Form 144 resale disclosure requirements.

How many Takeda (TAK) ADSs are planned to be sold and on which exchange?

The filing lists a planned sale of 15,188 American Depositary Shares (ADSs) of Takeda on the NYSE, to be executed through Interactive Brokers LLC.

What is the reported market value of the Takeda (TAK) ADSs to be sold?

The aggregate market value of the 15,188 ADSs planned for sale is disclosed as $254,398.88, based on the price information used in the Form 144 calculation.

How many Takeda (TAK) shares are reported as outstanding in this filing?

The Form 144 reports that 143,310,556 shares of Takeda’s securities are outstanding, providing context for the relative size of the planned 15,188 ADS sale.

What Takeda (TAK) sales occurred in the past three months before this Form 144?

The filing notes that 38,982 ADSs were sold on July 1, 2026, related to Restricted Stock Unit Awards - Vested, categorized as compensation.

Are the Takeda (TAK) ADSs in this Form 144 linked to compensation awards?

Yes. The Form 144 indicates ADSs associated with Restricted Stock Unit Awards - Vested, and the prior 38,982 ADS sale on July 1, 2026 is classified as compensation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	15188	254398.88	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			38982	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)